Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer. Our unique Iovance TIL technology platform has generated novel cell therapies that are currently in clinical studies for multiple cancers.

We are adding to our talented team as we actively prepare for our initial commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area, with business offices in New York and Philadelphia and a research site in Tampa, Florida. Iovance is also constructing a state-of-the-art manufacturing facility in Philadelphia.